» Articles » PMID: 39475070

Multi-Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation

Overview
Date 2024 Oct 30
PMID 39475070
Authors
Affiliations
Soon will be listed here.
Abstract

The anaphylatoxins C3a and C5a are products of the complement cascade that play important and interrelated roles in health and disease. Both are potential targets for anti-inflammatory active immunotherapies in which a patient's own immune system is stimulated to produce therapeutic immune responses against problematic self-molecules. However, the complex and time-dependent interrelations between the two molecules make dual targeting challenging. To investigate a dual-target active immunotherapy against C3a and C5a and to systematically study the effect of varied degrees of responses against both targets, the study employed self-assembled peptide immunogens capable of displaying a broad range of epitope compositions and Design-of-Experiments (DoE) approaches. Peptide nanofibers contained B-cell epitopes of C3a and C5a in defined quantities, and intranasal immunization raised systemic and mucosal immunity against each target. In a lipopolysaccharide-induced model of sepsis, increasing anti-C5a responses are protective, whereas increasing anti-C3a responses are detrimental, and survival rates are negatively correlated with anti-C3a/anti-C5a IgG titer ratio. This work highlights the interplay between the two molecules by making use of a modular, defined, and easily adjusted biomaterial-based active immunotherapy platform.

References
1.
Hartwell B, Melo M, Xiao P, Lemnios A, Li N, Chang J . Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci Transl Med. 2022; 14(654):eabn1413. PMC: 9835395. DOI: 10.1126/scitranslmed.abn1413. View

2.
Hollmann T, Mueller-Ortiz S, Braun M, Wetsel R . Disruption of the C5a receptor gene increases resistance to acute Gram-negative bacteremia and endotoxic shock: opposing roles of C3a and C5a. Mol Immunol. 2007; 45(7):1907-15. PMC: 4294580. DOI: 10.1016/j.molimm.2007.10.037. View

3.
Ben-Horin S, Kopylov U, Chowers Y . Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2013; 13(1):24-30. DOI: 10.1016/j.autrev.2013.06.002. View

4.
Peng Q, Li K, Sacks S, Zhou W . The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets. 2009; 8(3):236-46. DOI: 10.2174/187152809788681038. View

5.
Hainline K, Freire Haddad H, Gilpin A, Curvino E, Varghese S, Collier J . Active immunotherapy for C5a-mediated inflammation using adjuvant-free self-assembled peptide nanofibers. Acta Biomater. 2024; 179:83-94. PMC: 11045302. DOI: 10.1016/j.actbio.2024.02.042. View